Zenosense, Inc. (OTCBB:ZENO) announced a private placement of common shares with an accredited investor for gross proceeds of $475,000 on April 8, 2014. The company will first issue 55,556 shares at $0.45 per share for gross proceeds of $25,000. The company will further issue 900,000 shares at $0.50 per share for gross proceeds of $450,000.

The 900,000 shares will be issued subject to two conditions, the company successfully achieving the goal of its stage one development, which is defined as Prototype MRSA/SA sensor to be developed from Sgenia technology, having a capacity to detect MRSA and/or SA contamination under the development and exclusive license agreement, dated December 3, 2013, by and among the company, Sgenia Industrial, S.L, Sgenia Soluciones, S.L., and ZENON Biosystem, S and the company maintaining the continuing listing, without interruption, of its common stock on at least one of the OTCQB, OTCQX or equivalent replacement exchange. Once these conditions are met, the investor will first purchase 300,000 shares for $150,000 and within a month of the first purchase for 300,000 shares, the investor will make three additional consecutive monthly purchases each consisting of 200,000 shares. The company will issue securities pursuant to exemption provided under Regulation D. Andrew D. Hudders of Golenbock Eiseman Assor Bell & Peskoe LLP will act as a legal advisor to the company.